HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human raji cell mhc class I and II expression by gp41

Ying-Hua Chen,Günther Böck,Rolf Vornhagen,Franz Steindl,Hermann Katinger,Manfred P. Dierich
DOI: https://doi.org/10.1016/0161-5890(94)90092-2
IF: 4.174
1994-01-01
Molecular Immunology
Abstract:Based on our findings, that HIV-1 soluble gp41 could bind to several proteins on the human. T, B and monocyte cells independently of CD4, we examined the effect of HIV-1 soluble gp41 (sgp41; Env amino acids 539–684) on surface expression of MHC I and II, ICAM-1 and CD21 molecules on human Raji cells. Flow cytometry (FACS) analysis demonstrated that sgp41 could selectively enhance MHC class I and II expression on Raji cells, but did not increase expression of other cell surface antigens, such as, CD21 and CD54 (ICAM-1). Soluble gp41 could also enhance MHC class I and II expression on another human B cell line, Bjab. The sgp41-dependent enhancement of the MHC class I and II expression on Raji cells is time- and dose-dependent. The sgp41 enhancement effect on the MHC antigen expression could be inhibited by the gp41-binding proteins of 45, 49 and 62 kD (isolated from Raji-lysate) which could inhibit the sgp41-binding to Raji cells. Interestingly, this sgp41-dependent enhancement of the MHC class I and II expression could also be inhibited by two mAbs to HIV-1 gp41, but not by a third mAb binding to a different site on gp41. These results demonstrate that HIV-1 sgp41 can selectively enhance the human Raji cell MHC class I and II antigen expression and this enhancement effect could be inhibited by the sgp41-binding proteins and anti-gp41 antibodies, and suggest that the sgp41-dependent enhancement is mediated by its binding to Raji membrane proteins of 45, 49 and 62 kD.
What problem does this paper attempt to address?